OneSource Specialty Pharma Limited has received a significant credit rating upgrade from India Ratings & Research (Ind-Ra). The company’s long-term rating has been enhanced to ‘IND A’ with a Positive Outlook, from ‘IND A-‘. The short-term rating remains affirmed at ‘IND A1’. This upgrade reflects the company’s strengthening business profile, successful commercialization of its DDC platform, and increasing contribution from commercial GLP-1 supplies.
OneSource Specialty Pharma Receives Rating Upgrade
OneSource Specialty Pharma Limited (OSPL) has been upgraded by India Ratings & Research (Ind-Ra), signaling a stronger financial outlook for the company. The upgrade encompasses the company’s bank loan facilities, with the long-term rating moving to ‘IND A’ from ‘IND A-‘ and carrying a Positive Outlook. The short-term rating has been affirmed at ‘IND A1’.
This positive rating action is attributed to OSPL’s strengthening business profile. Key drivers include the successful commercialization of its drug-device combination (DDC) platform and a growing contribution from its commercial glucagon-like peptide-1 (GLP-1) supplies. Ind-Ra highlights the company’s transition from a development-led to a supply-led revenue model, supported by new customer launches, long-term supply agreements, and capacity expansions.
Key Factors Driving the Upgrade
- Successful Commercialisation: The company’s ability to convert development projects into commercial supplies has improved revenue visibility and reduced execution risk.
- Expanding Capacity: OSPL is investing in capacity expansion to meet increasing demand, with an approximate USD100 million capex planned, largely funded by debt.
- Improving Operating Performance: While revenue saw a slight dip in FY26, EBITDA margins have shown improvement, with a healthy performance in 1QFY27.
- Diversified Business Model: OSPL benefits from a diversified contract development and manufacturing organisation (CDMO) platform across DDCs, biologics, sterile injectables, and softgels.
Outlook and Sensitivities
The Positive Outlook indicates Ind-Ra’s expectation of continued improvement in OSPL’s business profile and credit metrics over the medium term. This is anticipated due to the ramp-up of commercial GLP-1 opportunities, increasing commercial supply agreement revenue, and capacity utilization. The agency anticipates leverage to decline below 2x by FY28.
Key Rating Drivers include:
- Strengths: Robust DDC platform commercialization, capacity expansion backed by customer commitments, and improving operating performance.
- Weaknesses: Regulatory and approval risks, foreign currency risk, and significant contingent liabilities related to an arbitration proceeding.
The details of the instruments and their ratings, including specific bank facilities, are provided in the accompanying documentation.
Source: BSE
